tbuckley/cabot-search huggingface dataset:
Reducing Overuse—Is Patient Safety the Answer?
Authors: Allison Lipitz-Snyderman, Deborah Korenstein
Journal: JAMA (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Screening for Depression Through a Glass Darkly—Reply
Authors: Mark Olfson, Carlos Blanco, Steven C. Marcus
Journal: JAMA Internal Medicine (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
Chlorpromazine, an Inhibitor of Intracellular Trafficking of FLT3-ITD and KIT D816V, Shows Prominent Anti-Leukemic Activities Against AML Cells and AML Stem Cells in Vitro and in Vivo.
Authors: Shinya Rai, Hirokazu Tanaka, Mai Suzuki, Akira Tanimura, Keiko Matsui, Toshio Watanabe, Yuzuru Kanakura, Itaru Matsumura
Journal: Blood (2014)
The Effectiveness of Anti-CD20 in Children with Refractory Chronic Immune Trhombocytopenic Purpura or Hemophilia with Inhibitors.
Authors: Maria Moschovi, Georgios Trimis, Sophia Aronis, Heleni Platokouki, Eleni Vrachnou, Athina Xaidara, Fotini Tzortzatou-Stathopoulou
Journal: Blood (2004)
Intensification of the Regimen Fludarabine Melphalan with the Addition of 400 Cgy of Total Body Irradiation in Allogeneic Stem Cell Transplantation. It Is Feasible, Has a Good Anti-Leukemic Effect and a Low Toxicity
Authors: Amado J Karduss-Urueta, Giovanni Ruiz, Rosendo Perez, Alejo Jimenez, Angelica Cardona, Gloria Suarez, Luis R Gomez, Pedro Reyes
Journal: Blood (2015)
Identifying Ultra-High Risk Myeloma By Integrated Molecular Genetic and Gene Expression Profiling
Authors: Amy L Sherborne, Dil B Begum, Amy Price, David C Johnson, Sidra Ellis, Charlotte Smith, Fabio Mirabella, Karen Menezes, Scott Kimber, John R Jones, Charlotte Pawlyn, Richard S Houlston, Nigel H. Russell, Matthew W Jenner, Gordon Cook, Alina Striha, Corinne Collett, Anna Waterhouse, Walter M Gregory, David A Cairns, Mark T Drayson, Roger G Owen, Faith E Davies, Gareth J Morgan, Graham H Jackson, Martin F Kaiser
Journal: Blood (2016)
Survival Trends in Adult T-Acute Lymphoblastic Leukemia / Lymphoma (ALL), a Comparative Analysis of 92 Patients By Year of Diagnosis
Authors: Hassan B Alkhateeb, Tasha Lin, Moussab Damlaj, Aref Al-Kali, Naseema Gangat, William J Hogan, Michelle Elliott, Grzegorz S. Nowakowski, Carrie Thompson, Thomas E. Witzig, Stephen M Ansell, Mark R Litzow, Mrinal M Patnaik
Journal: Blood (2015)
Carfilzomib in Combination with Bendamustine and Dexamethasone (CBd) in Relapsed and/or Refractory Patients with Multiple Myeloma: The Phase I/II EMN09 Study
Authors: Martin Gramatzki, Andreas Günther, Massimo Offidani, Monika Engelhardt, Paolo Corradini, Silvia Gentili, Vittorio Montefusco, Francesca Patriarca, Natalie Schub, Hermann Einsele, Pieter Sonneveld, Antonio Palumbo, Francesca Gay
Journal: Blood (2016)
Common genetic variation and risk of gallbladder cancer in India: a case-control genome-wide association study
Authors: Sharayu Mhatre, Zhaoming Wang, Rajini Nagrani, Rajendra Badwe, Shubhada Chiplunkar, Balraj Mittal, Saurabh Yadav, Haoyu Zhang, Charles C Chung, Prachi Patil, Stephen Chanock, Rajesh Dikshit, Nilanjan Chatterjee, Preetha Rajaraman
Journal: The Lancet Oncology (2017)
Imatinib Treatment of Philadelphia Positive (Ph+) Chronic Myeloid Leukemia (CML). For Late Chronic Phase Patients Who Achieve a Complete Cytogenetic Response 5-Year Survival Is as High as for Early Chronic Phase Patients.
Authors: Ilaria Iacobucci, Giovanni Martinelli, M. Amabile, A. Poerio, S. Soverini, F. Castagnetti, S. Colarossi, A. Gnani, N. Testoni, M. Breccia, E. Abruzzese, B. Martino, D. Cilloni, G. Saglio, F. Pane, G. Rosti, M. Baccarani
Journal: Blood (2006)
Characterization of oral and gut microbiome temporal variability in hospitalized cancer patients
Authors: Jessica R. Galloway-Peña, Daniel P. Smith, Pranoti Sahasrabhojane, W. Duncan Wadsworth, Bryan M. Fellman, Nadim J. Ajami, Elizabeth J. Shpall, Naval Daver, Michele Guindani, Joseph F. Petrosino, Dimitrios P. Kontoyiannis, Samuel A. Shelburne
Journal: Genome Medicine (2017)

Understanding longitudinal variability of the microbiome in ill patients is critical to moving microbiome-based measurements and therapeutics into clinical practice. However, the vast majority of data regarding microbiome stability are derived from healthy subjects. Herein, we sought to determine intra-patient temporal microbiota variability, the factors driving such variability, and its clinical impact in an extensive longitudinal cohort of hospitalized cancer patients during chemotherapy. The stool (n = 365) and oral (n = 483) samples of 59 patients with acute myeloid leukemia (AML) undergoing induction chemotherapy (IC) were sampled from initiation of chemotherapy until neutrophil recovery. Microbiome characterization was performed via analysis of 16S rRNA gene sequencing. Temporal variability was determined using coefficients of variation (CV) of the Shannon diversity index (SDI) and unweighted and weighted UniFrac distances per patient, per site. Measurements of intra-patient temporal variability and patient stability categories were analyzed for their correlations with genera abundances. Groups of patients were analyzed to determine if patients with adverse outcomes had significantly different levels of microbiome temporal variability. Potential clinical drivers of microbiome temporal instability were determined using multivariable regression analyses. Our cohort evidenced a high degree of intra-patient temporal instability of stool and oral microbial diversity based on SDI CV. We identified statistically significant differences in the relative abundance of multiple taxa amongst individuals with different levels of microbiota temporal stability. Increased intra-patient temporal variability of the oral SDI was correlated with increased risk of infection during IC (P = 0.02), and higher stool SDI CVs were correlated with increased risk of infection 90 days post-IC (P = 0.04). Total days on antibiotics was significantly associated with increased temporal variability of both oral microbial diversity (P = 0.03) and community structure (P = 0.002). These data quantify the longitudinal variability of the oral and gut microbiota in AML patients, show that increased variability was correlated with adverse clinical outcomes, and offer the possibility of using stabilizing taxa as a method of focused microbiome repletion. Furthermore, these results support the importance of longitudinal microbiome sampling and analyses, rather than one time measurements, in research and future clinical practice.
Erratum: Corrigendum: Analyses of allele-specific gene expression in highly divergent mouse crosses identifies pervasive allelic imbalance
Authors: James J Crowley, Vasyl Zhabotynsky, Wei Sun, Shunping Huang, Isa Kemal Pakatci, Yunjung Kim, Jeremy R Wang, Andrew P Morgan, John D Calaway, David L Aylor, Zaining Yun, Timothy A Bell, Ryan J Buus, Mark E Calaway, John P Didion, Terry J Gooch, Stephanie D Hansen, Nashiya N Robinson, Ginger D Shaw, Jason S Spence, Corey R Quackenbush, Cordelia J Barrick, Randal J Nonneman, Kyungsu Kim, James Xenakis, Yuying Xie, William Valdar, Alan B Lenarcic, Wei Wang, Catherine E Welsh, Chen-Ping Fu, Zhaojun Zhang, James Holt, Zhishan Guo, David W Threadgill, Lisa M Tarantino, Darla R Miller, Fei Zou, Leonard McMillan, Patrick F Sullivan, Fernando Pardo-Manuel de Villena
Journal: Nature Genetics (2015)
Relationship Between Physical Activity, Body Mass Index, and Risk of Heart Failure
Authors: Ambarish Pandey, Michael LaMonte, Liviu Klein, Colby Ayers, Bruce M. Psaty, Charles B. Eaton, Norrina B. Allen, James A. de Lemos, Mercedes Carnethon, Philip Greenland, Jarett D. Berry
Journal: Journal of the American College of Cardiology (2017)
Cars in Leukemia: Relapse with Antigen-Negative Leukemia Originating from a Single B Cell Expressing the Leukemia-Targeting CAR
Authors: Simon Francis Lacey, Jun Xu, Marco Ruella, David M. Barrett, Irina Kulikovskaya, David E Ambrose, Prachi R. Patel, Tyler Reich, John Scholler, Farzana Nazimuddin, Joseph A. Fraietta, Shannon L Maude, Saar I. Gill, Bruce L Levine, Christopher L Nobles, Frederic D Bushman, Elena Orlando, Stephan A. Grupp, Carl H June, Jan Joseph Melenhorst
Journal: Blood (2016)
Human Papillomavirus infection and cervical lesions in HIV infected women on antiretroviral treatment in Thailand
Authors: Tristan Delory, Nicole Ngo-Giang-Huong, Samreung Rangdaeng, Nantasak Chotivanich, Aram Limtrakul, Chaiwat Putiyanun, Pornnapa Suriyachai, Wanmanee Matanasarawut, Tapnarong Jarupanich, Prateung Liampongsabuddhi, Isabelle Heard, Gonzague Jourdain, Marc Lallemant, Sophie Le Coeur, Kevin Zarca, Florence Brunet-Possenti, Alexandre Blake, Thomas Althaus, Céline Gallot, Alice Desbiolles, Florence Fayard, Fadia Dib, Diane Le Pluart, Myrtille Proute, Métrey Tiv
Journal: Journal of Infection (2017)
Oncotype DX and proliferation response to short-term preoperative endocrine therapy for chemotherapy decision in early breast cancer: Biomarker data from the prospective multicenter phase II/III WSG-ADAPT trial.
Authors: Oleg Gluz, Ulrike Nitz, Ronald Kates, Daniel Hofmann, Sherko Kümmel, Benno Nuding, Claudia Schumacher, Bahriye Aktas, Helmut Forstbauer, Nicolai Maass, Michael Wilhelm Braun, Mahdi Rezai, Manfred Kusche, Albert von der Assen, Steven Shak, Christer Svedman, Rachel Wuerstlein, Nadia Harbeck, Hans Heinrich Kreipe, Matthias Christgen
Journal: Journal of Clinical Oncology (2014)

524^ Background: WSG-ADAPT aims to optimize early breast cancer therapy within a genomically classified (by OncotypeDX) intermediate-risk group using individual endocrine sensitivity. Methods: WSG-ADAPT HR+/HER2- analyzes biomarker changes after 3 weeks of preoperative ET [aromatase inhibitors (AI) in postmenopausal, tamoxifen (Tam) in premenopausal women]. Overall, n=1760 patients (HR+/HER2-, pN0-1) with Recurrence Score (RS) 0-11 or RS 12-25 and post-Tx Ki-67<10% are treated by ET alone. Other RS 12-25 and all RS ≥26 patients are included in phase III CTx design (n=2200). Results: 1118 patients from 61 centers have been enrolled (01/2014); run-in phase analysis included 383 patients (median age 54 years, 175 Tam, 208 AI). RS distribution (≤11/12-25/≥26) was 23%/57%/20%; median relative Ki-67 decreases were 0.67/0.60/0.40 by RS groups (p=0.017). Median relative Ki-67 decrease was more pronounced in post- vs. premenopausal patients (75% vs. 38%; p<0.001). Mean PR (not ER) expression changes were also more pronounced in postmenopausal patients (-39.5 %- vs. -10.4%-units; p<0.001). Pre- and post-endocrine RS (n=187) are moderately correlated (rS =.70, p<.001); no significant RS change was seen (95% CI: -1.7 to 0.3). Absolute change in Ki-67 by IHC was correlated with change in RS proliferation (rS= .62, 95% CI: 0.52 to 0.7). Median ER expression by RT-PCR was higher in post- than premenopausal patients (10.25 vs. 9.3, p<0.001); median PR expression by RT-PCR trended oppositely (7.7 vs. 8.1, p=0.01). Baseline ER expression by RT-PCR (not IHC) was associated with relative Ki-67 decrease (rS=.29, p<0.001). Baseline Ki-67, menopausal status/endocrine agent, and RS were independent predictors for post-treatment Ki-67. Conclusions: Postmenopausal patients (mostly AI) and those with lower baseline RS showed stronger proliferation response to short preoperative endocrine therapy. The difference in outcome between early proliferation responders (>70%) treated with ET alone among pN0/N1 patients with RS 12-25 and those with RS<11 will be tested in the WSG-ADAPT HR+/HER2- main phase. Clinical trial information: NCT01779206.
Exploring therapeutic targets in pulmonary sarcomatoid carcinoma by comprehensive genomic profiling.
Authors: Xuewen Liu, Yuxia Jia, Yufeng Shen, Haiying Cheng, Sanjay Koul, Alain C. Borczuk, Balazs Halmos
Journal: Journal of Clinical Oncology (2014)

8073 Background: Pulmonary sarcomatoid carcinoma (SC) is a rare and highly aggressive lung tumor, and it is associated with poor prognosis and high rate of resistance to conventional chemotherapy. The molecular basis of the unique dual differentiation pattern is poorly defined. New therapeutic strategies based on better knowledge of the molecular pathogenesis for pulmonary SC are needed. We used SNP array and high-throughput sequencing technology to identify novel therapeutic molecular targets. Methods: Ten pairs of genomic DNA samples were extracted from fresh frozen tumor tissues and paired normal tissues of patients with pulmonary SC. Whole-exome sequencing at a median of 120× coverage for tumor samples and 60× coverage for normal samples was performed at the Columbia Genome Center. Validation by Illumina TruSeq panel was performed on DNA from formalin-fixed paraffin-embedded (FFPE) tissue from these tumors. In addition, ten of the top ranked genes were chosen for validation by Sanger sequencing on DNA from these 10 cases and an additional cohort of 18 FFPE extracted DNA samples of pulmonary SC. Isolated DNA was hybridized to Affymetrix 6.0 SNP arrays and compared to a control group of 689 lung adenocarcinomas from two cohorts. Results: Mutations in TP53 (7/10, 70%), KRAS (2/10, 20%) and PIK3CA (2/10, 20%) were detected by whole exome sequencing and separately validated by TruSeq Illumina panel. Eight of the 10 genes at the top of the rank list, including RASA1(2/10, 20%), RYR2 (2/10, 20%), CDH4 (2/10, 20%), CDH7 (2/10, 20%), LAMB4 (3/10, 30%), MET (2/10, 20%), SCAF1 (2/10, 20%), and LMTK2 (2/10, 20%), were validated using Sanger sequencing. The validation of these genes in the cohort of 18 DNA samples extracted from FFPE tumor tissues is ongoing and functional validation of novel actionable targets will be pursued. SNP array results clearly distinguished SC from adenocarcinoma samples with significant copy number increases in chromosome 3q,7, 8q, 11p, 11q and 17q. Conclusions: Our study has identified novel molecular events in pulmonary SC tumors via high-throughput sequencing and SNP array analysis. The findings will be helpful for the development of new therapeutic strategies for pulmonary SC.
Abstract B62: Role of the blood microenvironment in the upregulation of oncoproteins in circulating pancreatic cancer cells
Authors: Annachiara Mitrugno, Katherine Pelz, Rosalie Sears, Owen McCarty
Journal: Cancer Research (2017)

Abstract Background: Platelets are promoters of cancer cell proliferation at the metastatic niche, however the exact mechanism(s) by which platelets drive cancer cell proliferation remain ill-defined. The oncoprotein c-MYC, which governs neoplastic proliferation, is overexpressed in pancreatic tumors at the metastatic site as compared to primary tumors, with the overexpression of c-MYC indicative of a poor clinical outcome for patients with cancer. At present, the oncogenic pathways mediating c-MYC upregulation in metastatic cancer cells are largely unknown. Our exciting preliminary data demonstrate for the first time that platelets upregulate c-MYC protein levels in PANC-1 pancreatic cancer cells, suggesting a novel prometastatic role for platelets in pancreatic cancer. Aims: To define the mechanisms by which platelets upregulate c-MYC protein levels in PANC-1 pancreatic cancer cells. Methods: We utilized a co-culture platform to examine the effect of resting and thrombin-stimulated human platelets as well as platelet fractions (platelet-derived membrane bound molecules and soluble molecules) on c-MYC expression in PANC-1 cancer cells. Platelet inhibitors, including the GPIIbIIIa blocker Integrilin, were used to study the molecular mechanisms by which platelets upregulate c-MYC expression in cancer cells. Changes in c-MYC oncoprotein were detected by Western Blotting. The physical association between platelets and PANC-1 cancer cells was quantified by immunoblotting with an anti-GPIIb antibody against the platelet-specific integrin GPIIbIIIa. Results: Resting and activated platelets as well as platelet fractions induced an upregulation of c-MYC expression in PANC-1 cancer cells. The effect of platelets on c-MYC expression was largely dependent on direct contact with the cancer cells, as the preincubation of platelets with Integrilin reduced platelet-induced c-MYC expression. Conclusion: We show that the expression of c-MYC in PANC-1 cancer cells can be upregulated by platelets, revealing a novel mechanism of platelet action in the progression of cancer and suggesting that the overexpression of c-MYC at the metastatic niche may be inhibited through the use of platelet inhibitors. We are currently characterizing the molecular underpinnings of platelet-mediated c-MYC regulation with respect to the contribution of platelets to cancer cell proliferation and growth. Citation Format: Annachiara Mitrugno, Katherine Pelz, Rosalie Sears, Owen McCarty. Role of the blood microenvironment in the upregulation of oncoproteins in circulating pancreatic cancer cells. [abstract]. In: Proceedings of the AACR Special Conference on Engineering and Physical Sciences in Oncology; 2016 Jun 25-28; Boston, MA. Philadelphia (PA): AACR; Cancer Res 2017;77(2 Suppl):Abstract nr B62.
Feasibility of Daily and Weekly Symptom and Health-Related Quality of Life (HRQOL) Surveillance in Patients Receiving Hematopoietic Cell Transplantation (HCT)
Authors: William A Wood, Allison M Deal, Bryce B Reeve, Amy P Abernethy, Claudio L Battaglini, Yoon Hie Kim, Julia S Whitley, Charlotte Shatten, Robert N Irons, Amber N Essenmacher, Kimberly Wehner, Alicia Pinto, James Coghill, Paul M Armistead, Stefanie Sarantopoulos, Don A. Gabriel, Jonathan S Serody, Thomas C. Shea
Journal: Blood (2012)
Treating Borderline Personality Disorder With Psychotherapy
Authors: Peter Fonagy, Patrick Luyten, Anthony Bateman
Journal: JAMA Psychiatry (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Psychiatry HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Psychiatry journal
Mitigation of Irradiation Induced Potentially Lethal Damage (PLD) in Hematopoietic Cells by Mitochondrial Localized GS-Nitroxide, JP4-039
Authors: Kanika Gupta, Michael W Epperly, Darcy Franicola, Xichen Zhang, Joshua G Pierce, Peter Wipf, Joel Greenberger
Journal: Blood (2008)
How ACA Repeal Would Worsen the Opioid Epidemic
Authors: Peter D. Friedmann, Christina M. Andrews, Keith Humphreys
Journal: New England Journal of Medicine (2017)

Although the Affordable Care Act was not designed with the opioid epidemic in mind, it provides valuable tools for expanding access to medication treatment — tools that will be taken away if the president and Congress deliver on their promise to repeal the ACA.
Multigene signature for predicting prognosis of patients with 1p19q co-deletion diffuse glioma
Authors: Xin Hu, Emmanuel Martinez-Ledesma, Siyuan Zheng, Hoon Kim, Floris Barthel, Tao Jiang, Kenneth R Hess, Roel G W Verhaak
Journal: Neuro-Oncology (2017)

Co-deletion of 1p and 19q marks a diffuse glioma subtype associated with relatively favorable overall survival; however, heterogeneous clinical outcomes are observed within this category.We assembled gene expression profiles and sample annotation of 374 glioma patients carrying the 1p/19q co-deletion. We predicted 1p/19q status using gene expression when annotation was missing. A first cohort was randomly split into training (n = 170) and a validation dataset (n = 163). A second validation set consisted of 41 expression profiles. An elastic-net penalized Cox proportional hazards model was applied to build a classifier model through cross-validation within the training dataset.The selected 35-gene signature was used to identify high-risk and low-risk groups in the validation set, which showed significantly different overall survival (P = .00058, log-rank test). For time-to-death events, the high-risk group predicted by the gene signature yielded a hazard ratio of 1.78 (95% confidence interval, 1.02-3.11). The signature was also significantly associated with clinical outcome in the The Cancer Genome Atlas (CGA) IDH-mutant 1p/19q wild-type and IDH-wild-type glioma cohorts. Pathway analysis suggested that high risk was associated with increased acetylation activity and inflammatory response. Tumor purity was found to be significantly decreased in high-risk IDH-mutant with 1p/19q co-deletion gliomas and IDH-wild-type glioblastomas but not in IDH-wild-type lower grade or IDH-mutant, non-co-deleted gliomas.We identified a 35-gene signature that identifies high-risk and low-risk categories of 1p/19q positive glioma patients. We have demonstrated heterogeneity amongst a relatively new glioma subtype and provided a stepping stone towards risk stratification.
Identification of Potential Therapeutic Targets Using Genome-Wide Analysis of Alternative Splicing (AS) In Patients with Acute Myeloid Leukemia (AML)
Authors: Sophia Adamia, Hervé Avet-Loiseau, Laurence Lodé, Michal Bar-Natan, Sigitas Verselis, Edward Fox, Ilene Galinsky, Philippe Moreau, Richard Stone, James D. Griffin
Journal: Blood (2010)